Top

Published in:

01-11-2016 | Public Health Policy (T Gaziano, Section Editor)

Cardiovascular Complications of HIV in Endemic Countries

Authors: Matthew J. Feinstein, Milana Bogorodskaya, Gerald S. Bloomfield, Rajesh Vedanthan, Mark J. Siedner, Gene F. Kwan, Christopher T. Longenecker

Published in: Current Cardiology Reports | Issue 11/2016

Abstract

Effective combination antiretroviral therapy (ART) has enabled human immunodeficiency virus (HIV) infection to evolve from a generally fatal condition to a manageable chronic disease. This transition began two decades ago in high-income countries and has more recently begun in lower income, HIV endemic countries (HIV-ECs). With this transition, there has been a concurrent shift in clinical and public health burden from AIDS-related complications and opportunistic infections to those associated with well-controlled HIV disease, including cardiovascular disease (CVD). In the current treatment era, traditional CVD risk factors and HIV-related factors both contribute to an elevated risk of myocardial infarction, stroke, heart failure, and arrhythmias. In HIV-ECs, the high prevalence of persons living with HIV and growing prevalence of CVD risk factors will contribute to a growing epidemic of HIV-associated CVD. In this review, we discuss the epidemiology and pathophysiology of cardiovascular complications of HIV and the resultant implications for public health efforts in HIV-ECs.

World Health Organization. Global Health Observatory Data: Antiretroviral therapy (ART) coverage among all age groups; 2015.

Kazooba P, Kasamba I, Baisley K, Mayanja BN, Maher D. Access to, and uptake of, antiretroviral therapy in a developing country with high HIV prevalence: a population-based cohort study in rural Uganda, 2004-2008. Trop Med Int Health. 2012;17:e49–57.PubMedPubMedCentralCrossRef

World Health Organization. Antiretroviral therapy coverage in sub-Saharan Africa. 2016.

The World Bank Group. Antiretroviral therapy coverage (% of people living with HIV). 2016.

Himakalasa W, Grisurapong S, Phuangsaichai S. Access to antiretroviral therapy among HIV/AIDS patients in Chiang Mai province, Thailand. HIV AIDS (Auckl). 2013;5:205–13.

Palella Jr FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.PubMedCrossRef

Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–22.PubMedPubMedCentralCrossRef

French AL, Gawel SH, Hershow R, Benning L, Hessol NA, Levine AM, et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr. 2009;51:399–406.PubMedPubMedCentralCrossRef

Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–12.PubMedPubMedCentralCrossRef

10.

Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60:351–8.PubMedPubMedCentralCrossRef

11.

Paisible AL, Chang CC, So-Armah KA, Butt AA, Leaf DA, Budoff M, et al. HIV Infection, Cardiovascular Disease Risk Factor Profile, and Risk for Acute Myocardial Infarction. J Acquir Immune Defic Syndr. 2015;68:209–16.PubMedCrossRef

12.

Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59:1891–6.PubMedPubMedCentralCrossRef

13.

Canada PHAo. HIV/AIDS Epi Updates. Chapter 13: HIV/AIDS in Canada among people from countries where HIV is endemic; 2012.

14.

De Castro S, d’Amati G, Gallo P, Cartoni D, Santopadre P, Vullo V, et al. Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol. 1994;24:1018–24.PubMedCrossRef

15.

Herskowitz A, Vlahov D, Willoughby S, Chaisson RE, Schulman SP, Neumann DA, et al. Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol. 1993;71:955–8.PubMedCrossRef

16.

Levy WS, Simon GL, Rios JC, Ross AM. Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am J Cardiol. 1989;63:86–9.PubMedCrossRef

17.

Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171:737–43.PubMedPubMedCentral

18.

Freiberg M, Chang CC, Oursler KA, Gottdiener J, Gottlieb S, Warner A, et al. The Risk of and Survival with Preserved vs. Reduced Ejection Fraction Heart Failure by HIV Status. Presented March 4, 2013 at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, USA. 2013. Abstract 750; http://www.retroconference.org/2013b/Abstracts/47343.htm. Accessed 5 May 2016.

19.•

Al-Kindi SG, ElAmm C, Ginwalla M, Mehanna E, Zacharias M, Benatti R, et al. Heart failure in patients with human immunodeficiency virus infection: Epidemiology and management disparities. Int J Cardiol. 2016;218:43–6. In a large electronic health record database of US health systems, the HIV-associated risk of heart failure appears to be higher in women compared to men.PubMedCrossRef

20.

Blaylock JM, Byers DK, Gibbs BT, Nayak G, Ferguson M, Tribble DR, et al. Longitudinal assessment of cardiac diastolic function in HIV-infected patients. Int J STD AIDS. 2012;23:105–10.PubMedCrossRef

21.

Cerrato E, D’Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J. 2013;34:1432–6.PubMedCrossRef

22.

Hsue PY, Hunt PW, Ho JE, Farah HH, Schnell A, Hoh R, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail. 2010;3:132–9.PubMedCrossRef

23.

Mondy KE, Gottdiener J, Overton ET, Henry K, Bush T, Conley L, et al. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. Clin Infect Dis. 2011;52:378–86.PubMedCrossRef

24.

Thiara DK, Liu CY, Raman F, Mangat S, Purdy JB, Duarte HA, et al. Abnormal Myocardial Function Is Related to Myocardial Steatosis and Diffuse Myocardial Fibrosis in HIV-Infected Adults. J Infect Dis. 2015;212:1544–51.PubMedPubMedCentralCrossRef

25.

Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med. 1997;155:990–5.PubMedCrossRef

26.

Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest. 1991;100:1268–71.PubMedCrossRef

27.

Almodovar S, Knight R, Allshouse AA, Roemer S, Lozupone C, McDonald D, et al. Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retroviruses. 2012;28:607–18.PubMedPubMedCentralCrossRef

28.

Barnett CF, Hsue PY. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med. 2013;34:283–92.PubMedPubMedCentralCrossRef

29.

Hsue PY, Deeks SG, Farah HH, Palav S, Ahmed SY, Schnell A, et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS. 2008;22:825–33.PubMedPubMedCentralCrossRef

30.

Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177:108–13.PubMedCrossRef

31.

Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis. 2004;38:1178–85.PubMedCrossRef

32.

Hsu JC, Li Y, Marcus GM, Hsue PY, Scherzer R, Grunfeld C, et al. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol. 2013;61:2288–95.PubMedCrossRef

33.•

Klein DB, Leyden WA, Xu L, Chao CR, Horberg MA, Towner WJ, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015;60:1278–80. This retrospective cohort study of Kaiser Permanente patients demonstrated a reduction in the relative risk of myocardial infarction incidence between HIV-positive and HIV-negative patients, with the adjusted RR decreasing from 1.8 (95% CI 1.3-2.6) in 1996-1999 to 1.0 (95% CI 0.7-1.4) in 2010-2011.PubMedCrossRef

34.

Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993;76:1423–7.PubMed

35.

Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86:27–31.PubMedCrossRef

36.

Grunfeld C, Kotler DP, Shigenaga JK, Doerrler W, Tierney A, Wang J, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991;90:154–62.PubMedCrossRef

37.

Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–9.PubMedCrossRef

38.

Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007;8:280–7.PubMedCrossRef

39.

Currier JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Tebas P, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS. 2007;21:1137–45.PubMedCrossRef

40.

Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63–70.PubMedCrossRef

41.

Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents. 2003;22:89–99.PubMedCrossRef

42.

Distler O, Cooper DA, Deckelbaum RJ, Sturley SL. Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care. 2001;4:99–103.PubMedCrossRef

43.

Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35–43.PubMedCrossRef

44.

Services USDoHaH. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents; 2015.

45.•

Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60:1842–51. Integrase inhibitors are newer antiretroviral drugs that are less metabolically toxic and are associated with more favorable changes in low-denstiy lipoprotein and triglycerides compared to protease inhibitors.PubMedPubMedCentralCrossRef

46.

Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011;25:185–95.PubMedCrossRef

47.

Petoumenos K, Worm S, Reiss P, de Wit S, d’Arminio Monforte A, Sabin C, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med. 2011;12:412–21.PubMedPubMedCentralCrossRef

48.

Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Pedersen C, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727–34.PubMedCrossRef

49.

Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953–60.PubMedCrossRef

50.

Sabin CA. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D : A : D study: a multi-cohort collaboration (vol 371, pg 1417, 2008). Lancet 2008;372:292-292.

51.

Lundgren JD, Neuhaus J, Babiker A, Cooper D, Duprez D, Ei-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. Aids. 2008;22:F17–24.CrossRef

52.

Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.PubMedCrossRef

53.

Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr. 2011;56:36–43.PubMedPubMedCentralCrossRef

54.

Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS. 2010;24:1897–905.PubMedPubMedCentralCrossRef

55.

Strategies for Management of Antiretroviral Therapy Study G, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.CrossRef

56.

Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dube MP, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008;52:569–76.PubMedPubMedCentralCrossRef

57.

Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204:1227–36.PubMedPubMedCentralCrossRef

58.

Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24:243–53.PubMedPubMedCentralCrossRef

59.

Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059–67.PubMedPubMedCentralCrossRef

60.

Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis. 2013;208:1436–42.PubMedPubMedCentralCrossRef

61.

Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.PubMedCrossRef

62.

Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One. 2011;6, e15924.PubMedPubMedCentralCrossRef

63.

Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534–43.PubMedCrossRef

64.

Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC, et al. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc. 2012;1.

65.

Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268–73.PubMedPubMedCentralCrossRef

66.

Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5, e78.PubMedPubMedCentralCrossRef

67.

Kabrhel C, Mark Courtney D, Camargo Jr CA, Plewa MC, Nordenholz KE, Moore CL, et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med. 2010;17:589–97.PubMedPubMedCentralCrossRef

68.

Neuhaus J, Jacobs Jr DR, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788–95.PubMedPubMedCentralCrossRef

69.

Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55:316–22.PubMedPubMedCentralCrossRef

70.

Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5, e203.PubMedPubMedCentralCrossRef

71.

Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, et al. Arterial inflammation in patients with HIV. JAMA. 2012;308:379–86.PubMedPubMedCentralCrossRef

72.

McKibben RA, Margolick JB, Grinspoon S, Li X, Palella Jr FJ, Kingsley LA, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. J Infect Dis. 2015;211:1219–28.PubMed

73.

Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23:1841–9.PubMedPubMedCentralCrossRef

74.

Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, et al. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol. 2012;109:742–7.PubMedCrossRef

75.

Post WS, Budoff M, Kingsley L, Palella Jr FJ, Witt MD, Li X, et al. Associations Between HIV Infection and Subclinical Coronary Atherosclerosis. Ann Intern Med. 2014;160:458–67.PubMedPubMedCentralCrossRef

76.

Ho JE, Scherzer R, Hecht FM, Maka K, Selby V, Martin JN, et al. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS. 2012;26:1115–20.PubMedCrossRef

77.

Baker JV, Henry WK, Patel P, Bush TJ, Conley LJ, Mack WJ, et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis. 2011;53:826–35.PubMedPubMedCentralCrossRef

78.

Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation. 2004;109:316–9.PubMedCrossRef

79.

McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012;26:1371–85.PubMedPubMedCentralCrossRef

80.

Almodovar S, Hsue PY, Morelli J, Huang L, Flores SC, Lung HIVS. Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 Nef. Proc Am Thorac Soc. 2011;8:308–12.PubMedPubMedCentralCrossRef

81.

Barnett CF, Hsue PY, Machado RF. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA. 2008;299:324–31.PubMedCrossRef

82.

Hofmann U, Frantz S. Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction. Circ Res. 2015;116:354–67.PubMedCrossRef

83.

Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015;2:e52–63.PubMedPubMedCentralCrossRef

84.

Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation. 1995;91:161–70.PubMedCrossRef

85.•

White JR, Chang CC, So-Armah KA, Stewart JC, Gupta SK, Butt AA, et al. Depression and Human Immunodeficiency Virus Infection Are Risk Factors for Incident Heart Failure Among Veterans: Veterans Aging Cohort Study. Circulation. 2015;132:1630–8. This prospective cohort study demonstrated that both major depressive disorder and HIV were independent risk factors for developing heart failure, with HIV patients with MDD having a hazard ratio of 1.63 (95% CI 1.28-2.09, p<0.001) compared to HIV-negative patients without MDD.PubMedPubMedCentralCrossRef

86.•

Bloomfield GS, Alenezi F, Barasa FA, Lumsden R, Mayosi BM, Velazquez EJ. Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. JACC Heart Fail. 2015;3:579–90. The antiretroviral era has significantly changed the epidemiology of heart failure in both the high-income countries as well as the lower/middle income countries. As ART is more available, more traditional and ART-related risk factors play a role in HF incidence, but populations with no access to ART will continue to develop HF from HIV-related factors.PubMedPubMedCentralCrossRef

87.

Holloway CJ, Ntusi N, Suttie J, Mahmod M, Wainwright E, Clutton G, et al. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation. 2013;128:814–22.PubMedCrossRef

88.

Iacobellis G, Pellicelli AM, Sharma AM, Grisorio B, Barbarini G, Barbaro G. Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Cardiol. 2007;99:1470–2.PubMedCrossRef

89.

El Hattaoui M, Charei N, Boumzebra D, Aajly L, Fadouach S. Prevalence of cardiomyopathy in HIV infection: prospective study on 158 HIV patients. Med Mal Infect. 2008;38:387–91.PubMedCrossRef

90.

Olusegun-Joseph DA, Ajuluchukwu JN, Okany CC, Mbakwem AC, Oke DA, Okubadejo NU. Echocardiographic patterns in treatment-naive HIV-positive patients in Lagos, south-west Nigeria. Cardiovasc J Afr. 2012;23:e1–6.PubMedPubMedCentralCrossRef

91.

Eholie SP, Lacombe K, Krain A, Diallo Z, Ouiminga M, Campa P, et al. Metabolic disorders and cardiovascular risk in treatment-naive HIV-infected patients of sub-saharan origin starting antiretrovirals: impact of westernized lifestyle. AIDS Res Hum Retroviruses. 2015;31:384–92.PubMedCrossRef

92.•

Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol. 2013;42:1754–71. HIV-positive subjects had lower BMI, higher triglyceride levels, lower mean HDL levels, and lower blood pressure. ART treatment was associated with higher LDL and HDL levels as well as lower HgbA1C levels.PubMedCrossRef

93.

Mensah GA, Roth GA, Sampson UK, Moran AE, Feigin VL, Forouzanfar MH, et al. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990-2013: a systematic analysis of data from the Global Burden of Disease Study 2013. Cardiovasc J Afr. 2015;2015(26):S6–S10.CrossRef

94.

Narayan KM, Miotti PG, Anand NP, Kline LM, Harmston C, Gulakowski 3rd R, et al. HIV and noncommunicable disease comorbidities in the era of antiretroviral therapy: a vital agenda for research in low- and middle-income country settings. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S2–7.PubMedCrossRef

95.

Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012;172:1386–94.PubMedCrossRef

96.••

Bloomfield GS, DeLong AK, Akwanalo CO, Hogan JW, Carter EJ, Aswa DF, et al. Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure: A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. Glob Heart. 2016;11:97–107. This case-controlled study showed that dilated cardiomyopathy and ischemic cardiomyopathy were the most common cause of heart failure in rural Kenya. In a population with a baseline HIV prevalence of 16%, HIV was the cause of heart failure in 8% of male cases and 9% of female cases.PubMedCrossRef

97.

Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J. 2012;33:866–74.PubMedCrossRef

98.

Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood). 2007;26:13–24.PubMedCentralCrossRef

99.

Rivera-Andrade A, Luna MA. Trends and heterogeneity of cardiovascular disease and risk factors across Latin American and Caribbean countries. Prog Cardiovasc Dis. 2014;57:276–85.PubMedCrossRef

100.

Barnighausen T, Welz T, Hosegood V, Batzing-Feigenbaum J, Tanser F, Herbst K, et al. Hiding in the shadows of the HIV epidemic: obesity and hypertension in a rural population with very high HIV prevalence in South Africa. J Hum Hypertens. 2008;22:236–9.PubMedCrossRef

101.

Malaza A, Mossong J, Barnighausen T, Newell ML. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS One. 2012;7, e47761.PubMedPubMedCentralCrossRef

102.

Temu TM, Kirui N, Wanjalla C, Ndungu AM, Kamano JH, Inui TS, et al. Cardiovascular health knowledge and preventive practices in people living with HIV in Kenya. BMC Infect Dis. 2015;15:421.PubMedPubMedCentralCrossRef

103.

Guthold R, Louazani SA, Riley LM, Cowan MJ, Bovet P, Damasceno A, et al. Physical activity in 22 African countries: results from the World Health Organization STEPwise approach to chronic disease risk factor surveillance. Am J Prev Med. 2011;41:52–60.PubMedCrossRef

104.

Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380:247–57.PubMedCrossRef

105.

Kavishe B, Biraro S, Baisley K, Vanobberghen F, Kapiga S, Munderi P, et al. High prevalence of hypertension and of risk factors for non-communicable diseases (NCDs): a population based cross-sectional survey of NCDS and HIV infection in Northwestern Tanzania and Southern Uganda. BMC Med. 2015;13:126.PubMedPubMedCentralCrossRef

106.

Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D. The burden of non-communicable diseases in South Africa. Lancet. 2009;374:934–47.PubMedCrossRef

107.

Kotwani P, Kwarisiima D, Clark TD, Kabami J, Geng EH, Jain V, et al. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health. 2013;13:1151.PubMedPubMedCentralCrossRef

108.

Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Intern Emerg Med. 2016;11:299–305.PubMedPubMedCentralCrossRef

109.

Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation. 2005;112:3562–8.PubMedCrossRef

110.

Tulloch-Reid MK, Younger NO, Ferguson TS, Francis DK, Abdulkadri AO, Gordon-Strachan GM, et al. Excess Cardiovascular Risk Burden in Jamaican Women Does Not Influence Predicted 10-Year CVD Risk Profiles of Jamaica Adults: An Analysis of the 2007/08 Jamaica Health and Lifestyle Survey. PLoS One. 2013;8, e66625.PubMedPubMedCentralCrossRef

111.

Diaz AA, Tringler MF. Prevalence of hypertension in rural populations from Ibero-America and the Caribbean. Rural Remote Health. 2014;14:2591.PubMed

112.

James J, Soyibo AK, Hurlock L, Gordon-Strachan G, Barton EN. Cardiovascular risk factors in an eastern Caribbean island: prevalence of non-communicable chronic diseases and associated lifestyle risk factors for cardiovascular morbidity and mortality in the British Virgin Islands. West Indian Med J. 2012;61:429–36.PubMedCrossRef

113.

Pierce L, Shannon A, Sonnenfeld J, Pearlmutter M, Previl H, Forrester JE. Hypertension prevalence and knowledge assessment in rural Haiti. Ethn Dis. 2014;24:213–9.PubMed

114.

Otgontuya D, Oum S, Palam E, Rani M, Buckley BS. Individual-based primary prevention of cardiovascular disease in Cambodia and Mongolia: early identification and management of hypertension and diabetes mellitus. BMC Public Health. 2012;12:254.PubMedPubMedCentralCrossRef

115.•

Chanthong P, Lapphra K, Saihongthong S, Sricharoenchai S, Wittawatmongkol O, Phongsamart W, et al. Echocardiography and carotid intima-media thickness among asymptomatic HIV-infected adolescents in Thailand. AIDS. 2014;28:2071–9. Few studies of CVD in HIV-ECs have been done outside of sub-Saharan Africa. This study from Thailand showed that HIV+ adolescents on protease inhibitors had higher triglycerides and increased carotid intima media thickness compared to healthy controls.PubMedPubMedCentralCrossRef

116.

Janssens B, Van Damme W, Raleigh B, Gupta J, Khem S, Soy Ty K, et al. Offering integrated care for HIV/AIDS, diabetes and hypertension within chronic disease clinics in Cambodia. Bull World Health Organ. 2007;85:880–5.PubMedPubMedCentral

117.

Kagaruki GB, Mayige MT, Ngadaya ES, Kimaro GD, Kalinga AK, Kilale AM, et al. Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions. BMC Public Health. 2014;14:1–9.CrossRef

118.

Kayima J, Nankabirwa J, Sinabulya I, Nakibuuka J, Zhu X, Rahman M, et al. Determinants of hypertension in a young adult Ugandan population in epidemiological transition-the MEPI-CVD survey. BMC Public Health. 2015;15:830.PubMedPubMedCentralCrossRef

119.

Khalsa A, Karim R, Mack WJ, Minkoff H, Cohen M, Young M, et al. Correlates of prevalent hypertension in a large cohort of HIV-infected women: Women’s Interagency HIV Study. AIDS. 2007;21:2539–41.PubMedCrossRef

120.•

Fourie CM, Schutte AE, Smith W, Kruger A, van Rooyen JM. Endothelial activation and cardiometabolic profiles of treated and never-treated HIV infected Africans. Atherosclerosis. 2015;240:154–60. Markers of endothelial activation (soluble intercellular and vascular cell adhesion molecules, sICAM and sVCAM) were increased in HIV-positive black South Africans, and did not return to normal following treatment with ART; however, selected markers of generalized inflammation (c-reactive protein and interleukin-6) did not defer between HIV-positive, HIV-positive on ART, or HIV-negative groups.PubMedCrossRef

121.

Krauskopf K, Van Natta ML, Danis RP, Gangaputra S, Ackatz L, Addessi A, et al. Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy. J Int Assoc Provid AIDS Care. 2013;12:325–33.PubMedPubMedCentralCrossRef

122.

Kwarisiima D, Balzer L, Heller D, Kotwani P, Chamie G, Clark T, et al. Population-Based Assessment of Hypertension Epidemiology and Risk Factors among HIV-Positive and General Populations in Rural Uganda. PLoS One. 2016;11, e0156309.PubMedPubMedCentralCrossRef

123.

Peck RN, Shedafa R, Kalluvya S, Downs JA, Todd J, Suthanthiran M, et al. Hypertension, kidney disease. HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study BMC Med. 2014;12:125.PubMed

124.••

Okello S, Asiimwe SB, Kanyesigye M, Muyindike WR, Boum Y, 2nd, Mwebesa BB, et al. D-dimer levels and traditional risk factors are associated with incident hypertension among HIV-infected individuals initiating antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr. 2016. doi:10.1097/QAI.0000000000001074. In a southwestern Ugandan population, initiation of antiretroviral therapy was associated with an increase in blood pressure. Traditional risk factors such as BMI, male gender, and age predicted incident hypertension better than markers of inflammation.

125.••

Nduka CU, Stranges S, Bloomfield GS, Kimani PK, Achinge G, Malu AO, et al. A plausible causal link between antiretroviral therapy and increased blood pressure in a sub-Saharan African setting: A propensity score-matched analysis. Int J Cardiol. 2016;220(400). In this study of HIV+ Nigerians, the estimated effect of ART on blood pressure was 7.85mmHg for systolic pressure and 7.45mmHg for diastolic pressure.

126.

Bloomfield GS, Hogan JW, Keter A, Sang E, Carter EJ, Velazquez EJ, et al. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. PLoS One. 2011;6, e22288.PubMedPubMedCentralCrossRef

127.

Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23:929–39.PubMedCrossRef

128.••

Gaziano TA, Abrahams-Gessel S, Alam S, Alam D, Ali M, Bloomfield G, et al. Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations. Glob Heart. 2016;11:37–46. e32. This study found strong agreement between laboratory-based and non-laboratory-based cardiovascular risk scores across a wide range of low- and middle-income countries, many of which are HIV-ECs.PubMedCrossRef

129.

Gaziano TA, Pandya A, Steyn K, Levitt N, Mollentze W, Joubert G, et al. Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations. BMC Med. 2013;11:170.PubMedPubMedCentralCrossRef

130.

Peer N, Lombard C, Steyn K, Gaziano T, Levitt N. Comparability of total cardiovascular disease risk estimates using laboratory and non-laboratory based assessments in urban-dwelling South Africans: the CRIBSA study. S Afr Med J. 2014;104:691–6.PubMedPubMedCentralCrossRef

131.

Sritara P. Twelve-year changes in vascular risk factors and their associations with mortality in a cohort of 3499 Thais: the Electricity Generating Authority of Thailand Study. Int J Epidemiol. 2003;32:461–8.PubMedCrossRef

132.

Krikke M, Hoogeveen RC, Hoepelman A, Visseren F, Arends JE. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models. HIV Med. 2016;17:289–97.PubMedCrossRef

133.

Longenecker CT, Eckard AR, McComsey GA. Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis. 2016;29:1–9.PubMedCrossRef

134.

Gaziano TA, Abrahams-Gessel S, Denman CA, Montano CM, Khanam M, Puoane T, et al. An assessment of community health workers’ ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in Bangladesh, Guatemala, Mexico, and South Africa: an observational study. Lancet Glob Health. 2015;3:e556–63.PubMedPubMedCentralCrossRef

135.

Lee ES, Vedanthan R, Jeemon P, Kamano JH, Kudesia P, Rajan V, et al. Quality Improvement for Cardiovascular Disease Care in Low- and Middle-Income Countries: A Systematic Review. PLoS One. 2016;11, e0157036.PubMedPubMedCentralCrossRef

136.•

Schoffelen AF, de Groot E, Tempelman HA, Visseren FL, Hoepelman AI, Barth RE. Carotid Intima Media Thickness in Mainly Female HIV-Infected Subjects in Rural South Africa: Association With Cardiovascular but Not HIV-Related Factors. Clin Infect Dis. 2015;61:1606–14. HIV was not an independent risk factor for increased carotid intima media thickness in this study. Risk factors for carotid vascular disease were traditional cardiovascular risk factors such as hypertension, diabetes, hyperlipidemia, and prior cardiovascular disease.PubMedCrossRef

137.

Vedanthan R, Kamano JH, Bloomfield GS, Manji I, Pastakia S, Kimaiyo SN. Engaging the Entire Care Cascade in Western Kenya: A Model to Achieve the Cardiovascular Disease Secondary Prevention Roadmap Goals. Glob Heart. 2015;10:313–7.PubMedCrossRef

138.••

Gupta N, Bukhman G. Leveraging the lessons learned from HIV/AIDS for coordinated chronic care delivery in resource-poor settings. Healthc (Amst). 2015;3:215–20. This article discusses ways in which existing HIV/AIDS infrastructure might be leveraged to improve care for other chronic conditions in HIV-ECs, including task-shifting, decentralization, retention and adherence strategies, patient groups and peer support, and global advocacy.CrossRef

139.

Pastakia SD, Ali SM, Kamano JH, Akwanalo CO, Ndege SK, Buckwalter VL, et al. Screening for diabetes and hypertension in a rural low income setting in western Kenya utilizing home-based and community-based strategies. Global Health. 2013;9:21.PubMedPubMedCentralCrossRef

140.

UNAIDS. Fact Sheet 2015. Geneva, Switzerland. 2015. http://www.unaids.org/sites/default/files/media_asset/20150901_FactSheet_2015_en.pdf. Accessed 5 May 2016.

Title: Cardiovascular Complications of HIV in Endemic Countries
Authors: Matthew J. Feinstein
Milana Bogorodskaya
Gerald S. Bloomfield
Rajesh Vedanthan
Mark J. Siedner
Gene F. Kwan
Christopher T. Longenecker
Publication date: 01-11-2016
Publisher: Springer US
Published in: Current Cardiology Reports / Issue 11/2016
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-016-0794-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Cardiovascular Complications of HIV in Endemic Countries

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2016

Integrating Out-of-Office Blood Pressure in the Diagnosis and Management of Hypertension

Access Options for Transcatheter Aortic Valve Replacement in Patients with Unfavorable Aortoiliofemoral Anatomy

Integrating Biomarkers and Imaging for Cardiovascular Disease Risk Assessment in Diabetes

Angiotensin-Neprilysin Inhibition as a Paradigm for All?

The Protective Role of Positive Well-Being in Cardiovascular Disease: Review of Current Evidence, Mechanisms, and Clinical Implications

Current Clinical Applications of Three-Dimensional Echocardiography: When the Technique Makes the Difference

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page